FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2167658920> ?p ?o ?g. }

• W2167658920 endingPage "11919" @default.
• W2167658920 startingPage "11916" @default.
• W2167658920 abstract "Many enzymes use ATP in signal-transducing processes or as an energy source. New fluorogenic ATP analogues signal ATP consumption by ubiquitin-like protein-activating enzymes in real time. Thus the inhibition and stimulation of these ATP-processing enzymes can be studied without auxiliary enzymes and reagents. β-Lapachone was identified as an inhibitor of the ubiquitin-activating enzyme UBA1 (see scheme; A=acceptor, D=donor). The conjugation of ubiquitin to proteins plays an important role in the regulation of numerous cellular processes.1 Deregulation of this pathway has been associated with different human disorders including cancer and neurodegenerative diseases.2 For ubiquitylation, ubiquitin is initially activated by a ubiquitin-activating enzyme (E1) at the expense of adenosine triphosphate (ATP; see Figure 1 a) to form a thioester bond between the C-terminal glycine of ubiquitin and the catalytic cysteine residue of E1.3 Subsequent transfer to a cysteine residue of a ubiquitin-conjugating enzyme (E2) initiates the conjugation of ubiquitin to a target protein (mostly to a lysine residue by means of an isopeptide bond), a process which in many cases requires the help of a ubiquitin ligase (E3).3 As UBA1 is one of only two known human E1 enzymes for ubiquitin,4 modulation of its activity may prove beneficial in the treatment of certain disorders. Hence, assays for studying the activation of ubiquitin by UBA1 directly and without the interfering effects of the downstream enzymatic cascade are important tools to analyze UBA1 activity and identify modulators of this enzyme. a) Mechanism of the activation of ubiquitin by UBA1. Ubiquitin is loaded onto UBA1 through the formation of a thioester bond with consumption of ATP. AMP: adenosine monophosphate, PP: pyrophosphate. b) Concept of signaling ATP consumption. The intact ATP analogue shows fluorescence of the acceptor (A) upon excitation of the donor (D) due to FRET. Upon cleavage by UBA1 direct donor fluorescence can be observed. So far, only a few assays that directly measure E1 activity have been described.5 However, these are laborious and not suitable for the continuous monitoring of E1 activity. In fact, until now no assay is available that allows the direct detection of ubiquitin activation in real time and that, for example, can be easily used to screen for E1 effectors. We, therefore, decided to elaborate on a conceptually novel assay: real-time detection of ubiquitin activation by monitoring the cleavage of an ATP analogue (Figure 1 b) that harbors two different fluorophores with the potential to undergo Förster resonance energy transfer (FRET). In the envisioned doubly labeled ATP analogue, excitation of the fluorescence donor (D) leads to transfer of the excitation energy to the fluorescence acceptor (A) whose fluorescence is monitored. Upon cleavage of the α/β anhydride bond of ATP, FRET is no longer possible and, thus, direct emission of the fluorescence donor can be detected. In this way, E1 activity results in a large change of fluorescence characteristics of the ATP analogue. Similar approaches based on the cleavage of FRET cassettes have been used for studying other hydrolyzing enzymes like proteases.6 For the envisaged time-resolved ATPase sensor (TRASE) approach two fluorophores have to be attached to ATP. As the N6 position of ATP has been proven to be an attractive site for modifications without compromising UBA1 activity,7 the second modification has to be placed at the phosphoanhydride chain so that the two fluorophores are spatially separated upon cleavage. As earlier studies revealed that phosphate esters of ATP are stable,8 we tested γ-modified triphosphate II and δ-modified tetraphosphate III in promoting the autoubiquitylation of E6AP, a reaction that involves UBA1 and the E2 enzyme UbcH5b (Figure 2 a,b). E6AP is an E3 ligase that has been causally associated with the development of three different human disorders: cervical cancer, Angelman syndrome, and autism spectrum disorders.9 As only the UBA1 reaction is ATP dependent, the appearance of polyubiquitylated E6AP (E6AP-Ub), which does not significantly migrate in the applied gel electrophoresis,10 and consequently decreased levels of free ubiquitin directly correlate with ATP consumption by UBA1. Interestingly it turned out that δ-modified tetraphosphate III is a superior substrate for UBA1 than the corresponding triphosphate II as evidenced by the more efficient consumption of ubiquitin (Figure 2 b). To validate these results, potential contaminations by unmodified ATP were removed by prior treatment with shrimp alkaline phosphatase (SAP), which does not hydrolyze II and III (Figure 2 b). Again it was observed that III is more efficiently processed than II. Ubiquitin activation by UBA1 is directly visualized in real time. a) Structures of ATP analogues used to explore the substrate scope of UBA1. b) Investigation of substrate scope of UBA1 for ATP analogues by the E6AP autoubiquitylation assay. UBA1 activity is monitored by the appearance of polyubiquitylated E6AP (E6AP-Ub) and a decrease of the band intensity of ubiquitin (Ub) in a Coomassie-stained SDS-PAGE. The samples pretreated with shrimp alkaline phosphatase (SAP) are indicated. The experiment was repeated three times. c) Synthesis of the doubly labeled probe IV. A) 1. EDC hydrochloride, DMF, 2.5 h, RT; 2. MeOH, 3 h, RT; 3. 6-azidohexylphosphate, 12 h, 40 °C, 23 %; B) 0.1 M NaOH, 4 h, RT; C) Sulfo-Cy5 NHS ester, 0.1 M NaHCO3, DMF, pH 8.7, 12 h, RT, 23 % (over two steps); D) TCEP, Et3N, H2O, MeOH, 4 h, RT, 74 %; E) Sulfo-Cy3 NHS ester, 0.1 M NaHCO3, DMF, pH 8.7, 12 h, RT, 61 %. d) Fluorescence spectra of the doubly labeled ATP analogue IV after incubation without (blue) and with (red) snake venom phosphodiesterase (SVPD), which quantitatively cleaves IV. e) Activation of ubiquitin by different concentrations of UBA1 is monitored directly by the cleavage of probe IV using the fluorescence intensity of the fluorescence donor (D) as readout. Values represent mean ±standard error of the mean of triplicates. With this information in hand, we next synthesized the doubly labeled ATP analogue IV (Figure 2 c). The fluorophores Sulfo-Cy3 and Sulfo-Cy5 were chosen, as they are especially well suited for FRET applications at short donor–acceptor distances.11 Our synthesis started with triphosphate 1.7 Modification of the phosphate chain was accomplished by activating the triphosphate with 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and subsequent addition of 6-azidohexylphosphate giving compound 2 in 23 % yield. Cleavage of the trifluoroacetamide (TFA) protecting group with sodium hydroxide, followed by coupling of the Sulfo-Cy5 N-hydroxysuccinimide (NHS) ester at pH 8.7 resulted in the singly labeled molecule 3 in 23 % yield. This could be further transformed by reduction of the azide with tris-(2-carboxyethyl)phosphine (TCEP) giving compound 4 in 74 % yield followed by coupling of the Sulfo-Cy3 NHS ester to obtain final compound IV in a yield of 61 %. After validation of the fluorescence properties of IV in a phosphodiesterase assay (Figure 2 d and Figure S1 in the Supporting Information), IV was tested as an ATP surrogate to be accepted by UBA1. Indeed, UBA1 used IV as a substrate as indicated by the appearance of ubiquitylated E6AP (Figure 2 b). Analyses of the levels of free ubiquitin revealed that far less ubiquitin was conjugated to E6AP in the presence of IV than in the presence of ATP. Furthermore, a titration experiment indicated that at least 250 μM IV is needed to reach a maximal reaction rate (Figure S2 in the Supporting Information). This shows that the KM value of IV is also considerably higher than that of ATP (4.7±1.0 μM).12 However, in view of the modification this is not unexpected. Finally, we used IV to monitor ubiquitin activation by UBA1 in real time in the absence of any other enzyme. We incubated IV and ubiquitin with different concentrations of UBA1 in a 384-well format and followed the fluorescence signal (Figure 2 e). We observed a time-dependent linear increase of the fluorescence intensity of the fluorescence donor Sulfo-Cy3 at 590 nm at all UBA1 concentrations tested. The rise in fluorescence correlated well with the concentration of UBA1 used (Figure S3 in the Supporting Information) demonstrating the practicability of our approach. Next, we checked if the ATP analogue IV optimized for UBA1 can also be used to study other E1 enzymes of ubiquitin-like modifiers (Ubls).13 Therefore, we investigated the activation of NEDD8 by APPBP1/UBA313, 14 and SUMO1 by SAE1/SAE213, 15 in the presence of IV (Figure 3 a). Indeed, all three E1 enzymes can be studied by TRASE as indicated by the rise of fluorescence intensity in the presence of the cognate Ubls. Furthermore, E1 activity could only be observed when the correct E1–Ubl pair was used. Scope of the method. a) Activation of ubiquitin and the Ubls SUMO1 and Nedd8 by cognate E1s. b) Stimulating effect of E2 enzymes on cognate E1s. Rise of fluorescence was calculated by linear fitting of the fluorescence intensity over time. % Stimulation was calculated from the rise of fluorescence at 590 nm in the presence of the respective E2 relative to the mean of the rise of the controls without E2. Values represent mean ±standard error of the mean of triplicates. To further explore the applicability, we tested the potential influence of E2 enzymes on E1 activity. As shown in Figure 3 b, we observed an increase in the activity of the different E1s in the presence of their cognate E2s, while the E1s were not stimulated by noncognate E2s. Thus, TRASE provides a simple tool to determine the specificities of E2s for E1 enzymes and in general, to identify positive and negative effectors of E1s. Inhibitors of UBA1 have been proposed to be potentially useful in the treatment of certain types of cancer.16 However, only a few UBA1 inhibitors have been described,16–18 which may be due to the fact that robust assays for directly monitoring UBA1 activity in a high-throughput format have not been available. Indeed, previous screens to identify UBA1 inhibitors either relied on cell-based assays that monitor the degradation of ubiquitylated target proteins18 or used the detection of ubiquitin chains in vitro.19 In these assays inhibition of all downstream enzymes of the ubiquitylation cascade has to be excluded during cumbersome hit validation. In contrast, TRASE monitors UBA1 activity directly (in the absence of any downstream enzyme or reagent) and, thus, appears to be ideally suited to identify specific UBA1 inhibitors. Furthermore, since the assay provides multiple time-resolved data points, compounds that unspecifically affect the fluorescence characteristics of IV can be easily excluded. To show the applicability of TRASE for identifying UBA1 inhibitors, we screened 1279 compounds that are either natural products or FDA-approved drugs. This resulted in the identification of five hits that inhibit UBA1 activity to at least 90 % (see also Figures S4 and S5 in the Supporting Information). Further characterization using the TRASE assay revealed that one compound, β-lapachone (Figure 4 a), inhibits E1 activity with an IC50 of (1.62±0.13) μM (Figure 4 b). This compound is also able to inhibit autoubiqitylation of E6AP with a similar IC50 of (1.59±0.07) μm (Figure 4 b and Figure S6 in the Supporting Information). β-Lapachone is known to have anticancerogenic and pro-apoptotic effects on different cancer cell lines,20 but has not yet been associated with inhibition of the ubiquitylation pathway. To obtain evidence that β-lapachone interferes with E1 activity in a physiologically relevant setting, we decided to investigate the inhibitory potential of β-lapachone in Xenopus laevis egg extract,21 which represents a valuable system to study the function of the ubiquitin pathway in regulating cell cycle progression. The metaphase-arrested extract was pretreated with β-lapachone or DMSO in an experimental setup that is commonly used for these kinds of assays.22 By addition of calcium, the metaphase arrest of the extract was relieved resulting in the activation of the E3 ubiquitin ligase Anaphase Promoting Complex/Cyclosome (APC/C)23 and, consequently, in the destruction of cyclin B. Indeed, in the presence of DMSO, cyclin B levels decreased indicating that it was ubiquitylated and subjected to proteasomal degradation (Figure 4 c). In contrast, the signal for cyclin B remained detectable for a prolonged time in the extract treated with β-lapachone. Thus, these data suggest that β-lapachone prevents the destruction of cyclin B by inhibiting the loading of E1 with ubiquitin in Xenopus laevis egg extracts. Inhibition of ubiquitin activation by β-lapachone. a) Structure of β-lapachone. b) Concentration dependence of UBA1 inhibition by β-lapachone measured by the TRASE (black squares) and the E6AP autoubiquitylation assay (red circles). Rise of fluorescence in the TRASE assay was calculated by linear fitting of the fluorescence intensity over time. Consumption of ubiquitin in the E6AP autoubiquitylation assay was calculated by quantifying the ubiquitin band. % Inhibition was calculated from these values relative to the positive and negative controls. Values represent mean ±standard error of the mean of triplicates. c) Calcium-induced degradation of cyclin B in Xenopus laevis egg extract pretreated with DMSO or 500 μM β-lapachone. Time is given in minutes; samples were analyzed by immunoblotting for cyclin B. Ubiquitin-dependent degradation of cyclin B is slowed down by β-lapachone, CSF: cell extract arrested in metaphase by cytostatin factor. Tubulin serves as loading control. The experiment was repeated three times. β-lap: β-lapachone. In summary, with TRASE we present a conceptually new method to monitor the activity of the ATP-consuming enzyme UBA1. The method is based on fluorogenic ATP analogues undergoing a large change in fluorescence characteristics upon enzymatic processing. The method can be used to monitor and quantify the activation of ubiquitin and ubiquitin-like proteins by their cognate E1s in the absence of the downstream enzyme cascade in real time in a facile and parallel fashion. Additionally, the presented approach is applicable to study effects of protein interactions on activity as exemplarily shown for E1–E2 interactions. This opens the perspective, for example, of using TRASE to screen for small molecules acting on E2 enzymes. Furthermore, we show that the method is well suited for high-throughput screening endeavors and identified β-lapachone as a novel inhibitor of UBA1. Finally, the presented assay may not only be useful for identifying positive and negative effectors of E1 enzymes, but also holds the potential for studying other ATP-cleaving enzymes. As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W2167658920 created "2016-06-24" @default.
• W2167658920 creator A5003542465 @default.
• W2167658920 creator A5022205362 @default.
• W2167658920 creator A5029663747 @default.
• W2167658920 creator A5030213335 @default.
• W2167658920 creator A5035335930 @default.
• W2167658920 creator A5035525469 @default.
• W2167658920 creator A5056154048 @default.
• W2167658920 creator A5057465808 @default.
• W2167658920 creator A5090225181 @default.
• W2167658920 date "2013-09-17" @default.
• W2167658920 modified "2023-10-18" @default.
• W2167658920 title "Fluorogenic ATP Analogues for Online Monitoring of ATP Consumption: Observing Ubiquitin Activation in Real Time" @default.
• W2167658920 cites W1513849811 @default.
• W2167658920 cites W1571934973 @default.
• W2167658920 cites W1963759365 @default.
• W2167658920 cites W1966222784 @default.
• W2167658920 cites W1982597520 @default.
• W2167658920 cites W1991841644 @default.
• W2167658920 cites W1991875927 @default.
• W2167658920 cites W1996015633 @default.
• W2167658920 cites W1999966378 @default.
• W2167658920 cites W2004250476 @default.
• W2167658920 cites W2005249317 @default.
• W2167658920 cites W2014673395 @default.
• W2167658920 cites W2022690300 @default.
• W2167658920 cites W2027213843 @default.
• W2167658920 cites W2029093937 @default.
• W2167658920 cites W2033221350 @default.
• W2167658920 cites W2040064715 @default.
• W2167658920 cites W2046984022 @default.
• W2167658920 cites W2049119654 @default.
• W2167658920 cites W2064062755 @default.
• W2167658920 cites W2067371211 @default.
• W2167658920 cites W2068965698 @default.
• W2167658920 cites W2087420281 @default.
• W2167658920 cites W2092093169 @default.
• W2167658920 cites W2092265639 @default.
• W2167658920 cites W2093403489 @default.
• W2167658920 cites W2099002508 @default.
• W2167658920 cites W2109980738 @default.
• W2167658920 cites W2113793543 @default.
• W2167658920 cites W2122268525 @default.
• W2167658920 cites W2123322767 @default.
• W2167658920 cites W2129324100 @default.
• W2167658920 cites W2138057005 @default.
• W2167658920 cites W2144114582 @default.
• W2167658920 cites W2160168027 @default.
• W2167658920 cites W2166987747 @default.
• W2167658920 cites W2174972892 @default.
• W2167658920 cites W2331308111 @default.
• W2167658920 cites W246914009 @default.
• W2167658920 cites W935855719 @default.
• W2167658920 doi "https://doi.org/10.1002/anie.201304723" @default.
• W2167658920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24105922" @default.
• W2167658920 hasPublicationYear "2013" @default.
• W2167658920 type Work @default.
• W2167658920 sameAs 2167658920 @default.
• W2167658920 citedByCount "25" @default.
• W2167658920 countsByYear W21676589202013 @default.
• W2167658920 countsByYear W21676589202014 @default.
• W2167658920 countsByYear W21676589202015 @default.
• W2167658920 countsByYear W21676589202016 @default.
• W2167658920 countsByYear W21676589202017 @default.
• W2167658920 countsByYear W21676589202018 @default.
• W2167658920 countsByYear W21676589202019 @default.
• W2167658920 countsByYear W21676589202020 @default.
• W2167658920 countsByYear W21676589202021 @default.
• W2167658920 crossrefType "journal-article" @default.
• W2167658920 hasAuthorship W2167658920A5003542465 @default.
• W2167658920 hasAuthorship W2167658920A5022205362 @default.
• W2167658920 hasAuthorship W2167658920A5029663747 @default.
• W2167658920 hasAuthorship W2167658920A5030213335 @default.
• W2167658920 hasAuthorship W2167658920A5035335930 @default.
• W2167658920 hasAuthorship W2167658920A5035525469 @default.
• W2167658920 hasAuthorship W2167658920A5056154048 @default.
• W2167658920 hasAuthorship W2167658920A5057465808 @default.
• W2167658920 hasAuthorship W2167658920A5090225181 @default.
• W2167658920 hasBestOaLocation W21676589202 @default.
• W2167658920 hasConcept C104317684 @default.
• W2167658920 hasConcept C12554922 @default.
• W2167658920 hasConcept C144024400 @default.
• W2167658920 hasConcept C185592680 @default.
• W2167658920 hasConcept C21951064 @default.
• W2167658920 hasConcept C25602115 @default.
• W2167658920 hasConcept C2779564974 @default.
• W2167658920 hasConcept C30772137 @default.
• W2167658920 hasConcept C36289849 @default.
• W2167658920 hasConcept C55493867 @default.
• W2167658920 hasConcept C86803240 @default.
• W2167658920 hasConcept C95444343 @default.
• W2167658920 hasConceptScore W2167658920C104317684 @default.
• W2167658920 hasConceptScore W2167658920C12554922 @default.
• W2167658920 hasConceptScore W2167658920C144024400 @default.
• W2167658920 hasConceptScore W2167658920C185592680 @default.
• W2167658920 hasConceptScore W2167658920C21951064 @default.
• W2167658920 hasConceptScore W2167658920C25602115 @default.

• next